[Rediscussion on hot issues of endocrine therapy for breast cancer]

Zhonghua Yi Xue Za Zhi. 2023 Sep 12;103(34):2647-2651. doi: 10.3760/cma.j.cn112137-20230524-00850.
[Article in Chinese]

Abstract

In the past decade, generated data of large-scale clinical research of endocrine therapy and the update of guidelines have changed clinical practice of breast cancer treatment. However, there are unresolved issues on endocrine therapy. Based on new evidences and clinical experience, we expounded our points on neoadjuvant endocrine therapy, CDK4/6 inhibitoradjuvant therapy, concepts of endocrine sensitivity and endocrine resistance, first-line treatment for metastatic breast cancer, treatment options after progression on CDK4/6 inhibitor and treatment ofvisceral crisis.

近10年来,乳腺癌内分泌治疗大型临床研究结果的相继发布以及指南的更新,改变了我们的临床实践。然而,实际应用中仍存在尚未解决的问题,为此我们结合乳腺癌学术进展和临床经验,就新辅助内分泌、细胞周期蛋白依赖性激酶4和6(CDK4/6)抑制剂辅助治疗、内分泌敏感和耐药的概念、复发转移一线治疗、CDK4/6抑制剂失败后和内脏危象的治疗选择等内分泌热点问题阐述自己的观点。.

Publication types

  • English Abstract

MeSH terms

  • Neoadjuvant Therapy*
  • Neoplasms*